Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Oncology Drugs in Phase I/II Clinical Development in TAIWAN

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Senhwa Biosciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              TAIWAN Taiwan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Nano medicine and Drug Delivery

              Participation Not Confirmed

              Update your events

              Senhwa Biosciences's Silmitasertib Receives Rare Pediatric Disease Designation from FDA for Treatment of Sonic Hedgehog Medulloblastoma

              Contact the Supplier

              Lead Product(s): Silmitasertib

              Therapeutic Area: Oncology Product Name: CX 4945

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 07, 2020

              Details:

              U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for company's drug Silmitasertib, a Casein Kinase 2 (CK2) inhibitor, being developed as a treatment for recurrent sonic hedgehog (SHH) medulloblastoma.

              OBI Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              TAIWAN Taiwan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Nano medicine and Drug Delivery

              Participation Not Confirmed

              Update your events

              OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cance...

              Contact the Supplier

              Lead Product(s): OBI-999

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 21, 2020

              Details:

              Second Orphan Drug Designation for OBI-999, Antibody-Drug Conjugate in combination with a validated payload (MMAE) & the antibody targeting Globo H, a glycolipid antigen found on multiple tumor types.

              PharmaCompass__DigitalAd